Deutsche Bank Maintains Eli Lilly Hold, $38.50 PT

Deutsche Bank maintained its Eli Lilly LLY Hold rating and $38.50 price target in a research report published today. In the report, Deutsche Bank states, " The upside risks to our Hold rating are that Effient sales exceed expectations, or the company does a large merger, both of which are unlikely, in our view. The primary downside risks are disappointing commercial sales for Effient, a slowdown for Cymbalta, additional pipeline disappointments, and a failure to achieve targeted cost-cutting measures." Shares of Eli Lilly closed today at $39.32, up 3.01% from Wednesday's market close.